Literature DB >> 23533337

Letters to the editor.

.   

Abstract

Year:  2013        PMID： 23533337      PMCID： PMC3603180     

Source DB:  PubMed          Journal:  Ochsner J        ISSN： 1524-5012


× No keyword cloud information.
  15 in total

Review 1.  Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.

Authors:  James J DiNicolantonio; Daniel G Hackam
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-01

Review 2.  Vasodilating versus first-generation β-blockers for cardiovascular protection.

Authors:  Hassan Fares; Carl J Lavie; Hector O Ventura
Journal:  Postgrad Med       Date:  2012-03       Impact factor: 3.840

3.  Atenolol in uncomplicated hypertension: time for changes.

Authors:  Alberto Morales Salinas
Journal:  Lancet Neurol       Date:  2010-07       Impact factor: 44.182

4.  The Mediterranean paradox for susceptibility factors in coronary heart disease extends to genetics.

Authors:  Oscar Lao; Isabelle Dupanloup; Guido Barbujani; Jaume Bertranpetit; Francesc Calafell
Journal:  Ann Hum Genet       Date:  2007-08-07       Impact factor: 1.670

Review 5.  Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).

Authors:  James J DiNicolantonio; Carl J Lavie; Hassan Fares; Arthur R Menezes; James H O'Keefe
Journal:  Am J Cardiol       Date:  2013-01-04       Impact factor: 2.778

6.  One-year cardiovascular event rates in outpatients with atherothrombosis.

Authors:  Ph Gabriel Steg; Deepak L Bhatt; Peter W F Wilson; Ralph D'Agostino; E Magnus Ohman; Joachim Röther; Chiau-Suong Liau; Alan T Hirsch; Jean-Louis Mas; Yasuo Ikeda; Michael J Pencina; Shinya Goto
Journal:  JAMA       Date:  2007-03-21       Impact factor: 56.272

7.  Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.

Authors:  Peter M Rothwell; Sally C Howard; Eamon Dolan; Eoin O'Brien; Joanna E Dobson; Bjorn Dahlöf; Neil R Poulter; Peter S Sever
Journal:  Lancet Neurol       Date:  2010-03-11       Impact factor: 44.182

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

Authors:  Sripal Bangalore; Gabriel Steg; Prakash Deedwania; Kevin Crowley; Kim A Eagle; Shinya Goto; E Magnus Ohman; Christopher P Cannon; Sidney C Smith; Uwe Zeymer; Elaine B Hoffman; Franz H Messerli; Deepak L Bhatt
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

10.  Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements.

Authors:  J M Neutel; H Schnaper; D G Cheung; W F Graettinger; M A Weber
Journal:  Am Heart J       Date:  1990-07       Impact factor: 4.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.